GlassScriptPhysician profile
Priyankkumar P Patel
NPI 1437460789
$34,129.42
in general payments reported to CMS, 2019-2025
28 companies · $19K in 2025
The $19K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $191 · 2021: $6,504 · 2022: $3,475 · 2023: $4,143 · 2024: $708 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Consulting Fee: $5,495 · Travel and Lodging: $2,839 · Food and Beverage: $1,587 · Education: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,370.00 |
| Consulting Fee | $5,495.00 |
| Travel and Lodging | $2,839.27 |
| Food and Beverage | $1,586.56 |
| Education | $300.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $18,343.86 | 2019-2025 | Imfinzi, Tagrisso |
| Eli Lilly and Company | $6,300.00 | 2021 | |
| Immunocore Limited | $3,918.06 | 2023 | Kimmtrak |
| Lilly USA, LLC | $3,027.88 | 2022-2025 | Verzenio |
| Daiichi Sankyo INC. | $568.68 | 2022-2024 | Injectafer |
| Pfizer INC. | $222.97 | 2019-2025 | |
| Astellas Pharma US INC | $213.95 | 2020-2025 | Vyloy, Padcev, Xtandi |
| Celgene Corporation | $198.52 | 2021-2025 | Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $188.32 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $146.76 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Novartis Pharmaceuticals Corporation | $140.00 | 2021-2025 | |
| Incyte Corporation | $124.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $120.79 | 2019-2025 | Opdivo |
| Emd Serono, INC. | $98.79 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $74.67 | 2024 | Pyrukynd |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $67.27 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $57.35 | 2019-2025 | Ultomiris |
| Genzyme Corporation | $53.94 | 2019-2020 | |
| Taiho Oncology, INC. | $42.55 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $38.12 | 2020-2021 | |
| Clovis Oncology, INC. | $32.20 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.88 | 2021 | |
| Verastem, INC. | $25.75 | 2019 | |
| Beigene USA, INC. | $23.92 | 2022 | |
| Genentech, INC. | $21.42 | 2024 | Herceptin, Alecensa, Columvi |
| Puma Biotechnology, INC. | $21.00 | 2021 | |
| Tempus Ai, INC | $16.33 | 2024 | |
| Abbvie INC. | $13.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priyankkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.